Department of Internal Medicine, Faculty of Medicine, Firat University, Elazig, Turkey.
Department of Medical Biology, Medical Faculty, Firat University, Elazig, Turkey.
Endokrynol Pol. 2020;71(5):397-403. doi: 10.5603/EP.a2020.0038. Epub 2020 Jun 29.
Meteorin-like (Metrnl), also known as subfatin, is a recently discovered adipokine with a favourable effect on insulin sensitivity. Studies have shown lower Metrnl levels in obese patients. However, data on its circulating levels in type 2 diabetes mellitus (T2DM) patients are contradictory. This study aims to evaluate serum Metrnl levels in T2DM patients and determine the relationship between serum Metrnl levels and insulin resistance in these patients.
This cross-sectional study was conducted among 150 participants. The study was carried out between June 2019 and December 2019 at the internal medicine outpatient clinic of a tertiary university hospital. The participants were divided into three groups: group 1 (control group, n = 50), group 2 (newly diagnosed T2DM, n = 50), and group 3 (long-standing diagnosed T2DM, n = 50). An enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of Subfatin (Metrnl), and the correlations of Metrnl level with anthropometric parameters, HOMA index, and biochemical measurements were assessed.
There was no statistically significant difference between the gender (p = 0.468) and age (p = 0.067) characteristics of the three groups. The Metrnl (subfatin) levels of the participants were as follows: control group - 20.05 (1.56-103.78); newly diagnosed T2DM group - 2.62 (1.25-103.78); and long-standing diagnosed T2DM group - 2.01 (0.80-19.84) pg/mL. The Metrnl (subfatin) levels of the participants in the control group were higher than in the participants in the newly diagnosed T2DM and long-standing diagnosed T2DM groups (p < 0.001). Subfatin demonstrated a negative correlation with insulin and HOMA-IR in the control group and long-standing diagnosed T2DM group.
The subfatin level was found to be higher in the healthy control group than in both diabetic patient groups. Subfatin level showed negative correlation with both insulin level and HOMA index. There was a relationship between subfatin and insulin resistance. Low levels of subfatin in the diabetic patient groups may play a role in the pathogenesis of T2DM by increasing insulin resistance.
类流星体蛋白(Metrnl),也被称为亚脂肪素,是一种新发现的具有改善胰岛素敏感性的脂肪因子。研究表明肥胖患者的 Metrnl 水平较低。然而,关于 2 型糖尿病(T2DM)患者循环 Metrnl 水平的数据存在争议。本研究旨在评估 T2DM 患者的血清 Metrnl 水平,并确定这些患者的血清 Metrnl 水平与胰岛素抵抗之间的关系。
这是一项横断面研究,共有 150 名参与者。该研究于 2019 年 6 月至 2019 年 12 月在一所三级大学医院的内科门诊进行。参与者被分为三组:第 1 组(对照组,n=50)、第 2 组(新诊断的 T2DM,n=50)和第 3 组(长期诊断的 T2DM,n=50)。采用酶联免疫吸附试验(ELISA)测量血清 Subfatin(Metrnl)水平,并评估 Metrnl 水平与人体测量参数、HOMA 指数和生化测量值的相关性。
三组之间的性别(p=0.468)和年龄(p=0.067)特征无统计学差异。参与者的 Metrnl(亚脂肪素)水平如下:对照组-20.05(1.56-103.78);新诊断的 T2DM 组-2.62(1.25-103.78);长期诊断的 T2DM 组-2.01(0.80-19.84)pg/ml。对照组参与者的 Metrnl(亚脂肪素)水平高于新诊断的 T2DM 组和长期诊断的 T2DM 组参与者(p<0.001)。在对照组和长期诊断的 T2DM 组中,亚脂肪素与胰岛素和 HOMA-IR 呈负相关。
与健康对照组相比,糖尿病患者组的亚脂肪素水平更高。亚脂肪素水平与胰岛素水平和 HOMA 指数呈负相关。亚脂肪素与胰岛素抵抗之间存在关系。糖尿病患者组亚脂肪素水平较低可能通过增加胰岛素抵抗在 2 型糖尿病发病机制中发挥作用。